Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-11-25

Clinical Trial Update: Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial [Phase 3]

View source ↗

Summary

Open-label extension update for a Phase 3 trial in epilepsy evaluating VRX-RET-E22-301; results posted after trial completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VRX-RET-E22-301

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2016-11-25